Search clinical trials for: AF is refractory to at least one antiarrhythmic medication

Total 484108 results

Abbott Medical Devices

Completed

STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial

Atrial Fibrillation

Spain, Canada, Italy, Norway
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Refractory Lymphoma | DLBCL | MYD88 Gene Mutation | Relapse | CD79A Gene Mutation | CD79B Gene Mutation
Dana-Farber Cancer Institute

Recruiting

Acalabrutinib in CNSL

Refractory Central Nervous System Lymphoma | Central Nervous System Lymphoma | Recurrent Central Nervous System Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Pfizer

Active, not recruiting

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Multiple Myeloma

United States, Canada, Spain, Belgium, United Kingdom, Australia, Japan, France, Germany, Poland
Memorial Sloan Kettering Cancer Center

Completed

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)

Non-Hodgkin's Lymphoma | CNS Lymphoma | CNS Brain Cancer

United States
Swedish Orphan Biovitrum

Completed

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (DISSOLVE II)

Chronic Gout

United States, Serbia, Georgia, Ukraine, Russian Federation
Janssen-Cilag Ltd.
Legend Biotech

Completed

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

Multiple Myeloma

Belgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

HIV Infection | Hepatocellular Carcinoma | Non-Hodgkin Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Kaposi Sarcoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable... and other conditions

United States
Abbott Medical Devices

Active, not recruiting

Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)

Neuropathic Pain | Refractory Pain | Chronic Low-Back Pain

United States
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Multiple Myeloma

China
Boehringer Ingelheim

Completed

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Leukemia, Lymphocytic, Chronic, B-Cell

United States
Celgene

Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Multiple Myeloma

China
Pfizer
UCB Pharma

Completed

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Canada, France, Spain, China, United Kingdom, Australia, Taiwan, Singapore, Korea, Republic of, Japan, Germany, Czechia, Poland, Italy, Netherlands, Argentina, Finland, Hungary, Sweden
Medtronic Atrial Fibrillation Solutions
Medtronic

Completed

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Symptomatic Paroxysmal Atrial Fibrillation (PAF)

Germany, Czechia, France, Hungary, Italy, Netherlands, Spain, Switzerland
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Multiple Myeloma

United States, Spain, Canada
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Colombia, Portugal, Ukraine, Canada, Netherlands, Sweden, Korea, Republic of, Chile, Brazil, Russian Federation, Hungary, Ireland, Mexico, Czechia
Janssen-Cilag International NV

Completed

Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

Multiple Myeloma
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

HIV Infections

United States, Puerto Rico, Italy
Hospices Civils de Lyon

Unknown

AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

Chronic Myeloid Leukemia

France
Geha Mental Health Center

Unknown

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Depression

Israel
The Third Affiliated Hospital of Guangzhou Medical...

Recruiting

Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery

cfHPV DNA in Plasma of Cervical Cancer Patients

China
National Research Center for Hematology, Russia
St. Petersburg State Pavlov Medical University; Federal State Budgetary Institution...

Recruiting

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Refractory Acute Myeloid Leukemia | Early Relapses of Acute Myeloid Leukemia

Russian Federation
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

Effectiveness and Tolerability of Eptinezumab (TACHIS)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment (RAISE)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Refractory Acute Leukemia | Pediatric Relapsed

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
University of Massachusetts, Worcester
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

Asthma Link Effectiveness Trial: Cluster Randomized Controlled Trial

Childhood Asthma

United States
Mayo Clinic

Not yet recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin Lymphoma

United States
Eli Lilly and Company

Not yet recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Overweight and Obesity

United States, Canada, Australia, Germany, Mexico, Argentina, Brazil, Hungary, Austria, India, Poland, Slovakia, Spain, Netherlands, Turkey, Czechia, United Kingdom, Denmark, Puerto Rico, France, Israel
Delta-Fly Pharma, Inc.

Not yet recruiting

Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Riphah International University

Recruiting

Comparison of Aerobic and Resistance Training on Exercise Capacity, Depression and Quality of Life in Hypothyroidism.

Comparison of Aerobic Exercise and Resistance Training

Pakistan
LLS PedAL Initiative, LLC
Kura Oncology

Not yet recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Relapsed/Refractory KMT2A-r Acute Leukemia | Relapsed/Refractory NUP98-r Acute Leukemia | Relapsed/Refractory NPM1-m Acute Leukemia
Florida International University
Ann & Robert H Lurie Children's Hospital of Chicago; Care Resource Community...

Not yet recruiting

mHealth + e-Navigator Stepped Care on ART Adherence in Latino MSM (Project STEP)

ART Adherence

United States
Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS

Myelodysplastic Syndrome With Excess Blasts | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Myelodysplastic Syndrome Acute Myeloid Leukemia
Nantes University Hospital

Not yet recruiting

Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia. (PENTILULA)

Acute Leukemia

France
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
Adriana Rossi

Not yet recruiting

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Roswell Park Cancer Institute

Not yet recruiting

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence

Acute Lymphoblastic Leukemia

United States
Children's Hospital of Soochow University

Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

AML, Childhood | C-KIT Mutation | Refractory AML | Relapse/Recurrence | Core Binding Factor Acute Myeloid Leukemia

China
Narendranath Epperla

Not yet recruiting

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid... and other conditions

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
AbbVie

Not yet recruiting

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
Eli Lilly and Company

Recruiting

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Elevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)

Taiwan, United States, Spain, Argentina, China, Italy, Australia, France, Canada, Japan, Belgium, Denmark, Germany, Hungary, Israel, Austria, Korea, Republic of, Brazil, Mexico, Netherlands, Romania, United Kingdom, Greece, Czechia, India, Slovak... and more
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France

Search clinical trials for: AF is refractory to at least one antiarrhythmic medication

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations